America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
On the occasion of the 2015 White House Conference on Aging, which marks the sixth such event since the first in 1961, National Association of Chain Drug Stores president and CEO Steve Anderson joined the dialogue by issuing a statement.
How hard is it to find $24 billion to offset the cost of repealing the medical device tax? As hard as it is “to find a cup of coffee at Starbucks.” That’s according to National Center for Policy Analysis senior fellow John R. Graham, in a Forbes commentary.
The average lost time worker's compensation claim for workers using opioid painkillers can total as much as $117,000 — 900% higher than the cost for workers who do not take opioid painkillers, the National Safety Council says.
Otsuka Pharmaceutical and H. Lundbeck A/S announced Friday that their new medication Rexulti (brexpiprazole) had been approved by the Food and Drug Administration as an adjunctive treatment for major depressive disorder (MDD) and a treament for schizophrenia.
As part of its continued commitment to the practice of pharmacy and the future of the profession, Cardinal Health this year will award a total of more than $1 million to 10 pharmacy schools across the country through its Cardinal Health Pharmacy Scholarship Program.
With just about one week to go before the start of Cardinal Health RBC 2015, DSN editor-in-chief Rob Eder caught up with Jon Giacomin, Cardinal Health CEO for the Pharmaceutical segment to talk about the upcoming conference, the state of the pharmacy business and more.